You Position: Home > Paper

The assessment of diabetic macular ischemia and the influence of intravitreal anti-vascular endothelial growth factor therapy to diabetic macular ischemia

( views:259, downloads:459 )
Author:
No author available
Journal Title:
Chinese Journal of Ocular Fundus Diseases
Issue:
3
DOI:
10.3760/cma.j.issn.1005-1015.2019.03.024
Key Word:
糖尿病视网膜病变/治疗;血管生成抑制剂/治疗应用;抗体,单克隆/治疗应用;综述;糖尿病黄斑缺血;Diabetic retinopathy/therapy;Angiogenesis inhibitors/therapeutic use;Antibodies,monoclonal/therapeutic use;Review;Diabetic macular ischemia

Abstract´╝Ü Diabetic macular ischemia (DMI) is one of the manifestation of diabetic retinopathy (DR).It could be associated with diabetic macular edema (DME),which may affect the vision of DR patients.FFA is the gold standard for the diagnosis of DMI,but with the advent of OCT angiography,a more convenient and diversified method for the evaluation of DMI has been developed,which makes more and more researchers start to study DMI.Intravitreal injection of anti-VEGF has become the preferred treatment for DME.When treating with DME patients,ophthalmologists usually avoid DMI patients.But if intravitreal anti-VEGF should be the contradiction of DME is still unclear.To provide references to the research,this article summarized the risk factors,assessment methods and influence of DMI.This article also analyzed the existing studies,aiming to offer evidences to a more reasonable and effective treatment decision for DME individual.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn